How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.34.

When did Rexahn Pharmaceuticals' stock split?

Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX) , Inovio Pharmaceuticals (INO) , Dynavax Technologies (DVAX) , Novavax (NVAX) , AcelRx Pharmaceuticals (ACRX) , Imunon (CLSN) , LadRx (CYTR) and SCYNEXIS (SCYX) .

NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free REXN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.81
▼
$2.24
52-Week Range: N/A

Volume: 2,579 shs
Average Volume: 162,968 shs
Market Capitalization: $8.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Rexahn Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

REXN Stock News Headlines

February 16, 2024 | morningstar.com

Aurinia Pharmaceuticals Inc AUPH

March 27, 2023 | benzinga.com

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 1, 2023 | thestreet.com

Rexahn: Holes Galore in Serdaxin Data

See More Headlines

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/07/2019
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:REXN
CUSIP: N/A
CIK: 1228627
Web: www.rexahn.com
Phone: (248) 681-9815
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -72.60%
Return on Assets: -55.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.37
Quick Ratio: 3.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.48 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,483,000
Free Float: N/A
Market Cap: $8.11 million
Optionable: Optionable
Beta: 0.98

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mina Patel Sooch
President, Chief Executive Officer & Director
Bernhard Hoffmann
Vice President-Corporate Development & Operations
Amy Rabourn
Chief Accounting Officer & Vice President-Finance
Konstantinos Charizanis
Senior Director-Market Strategy, R&D
Drey Coleman
Director-Clinical Operations & Vendor Management

Key Competitors

View All Competitors

REXN Stock Analysis - Frequently Asked Questions

How were Rexahn Pharmaceuticals' earnings last quarter?: Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.34.
When did Rexahn Pharmaceuticals' stock split?: Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of Rexahn Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Imunon (CLSN), LadRx (CYTR) and SCYNEXIS (SCYX).

This page (NASDAQ:REXN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

REXN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

REXN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info